Discover LAMPIRE’s monoclonal Bovine ultra-long CDR3 picobodies—compact, stable binding domains (3–5 kDa) derived from bovines. Using Single B-cell Sorting and Directed Sequencing, these antibodies advance targeted therapy development. In early preclinical stages, picobody-derived recombinant antibodies, including “knobbodies” and bispecific formats, show promise in binding viral and cancer epitopes. Unlock new possibilities in precision medicine with LAMPIRE’s Bovine B-cell technology.

Accelerate monoclonal antibody discovery with LAMPIRE’s Llama B-cell approach. Our proprietary Single Cell Sorting of target-positive Llama and Alpaca B cells enables rapid, cost-effective VHH binder identification, with sequences recovered in just three weeks. By eliminating phage or yeast library costs and duplicate clone screening, our method maximizes efficiency. Capture the full antibody repertoire to explore clonotype relationships by affinity and epitope. Streamline developability assessments with in silico analysis, and enhance output with optional sequence refinement and humanization.

LAMPIRE offers rabbit monoclonal antibodies with high specificity, minimal off-target effects, and broad antigen detection for research, diagnostics, and therapeutics. Our tailored immunization campaigns focus on a single animal for optimal results, with sera titer-based selection and PBMC/splenocyte extraction. Precision FACS analysis identifies antigen-positive B cells using a wide range of antigens. Our advanced NGS technology ensures complete VH and VK sequence recovery with full IP ownership. We offer recombinant mAb expression at scales from 100 µg to 1 gram, with multiple backbone options, and robust 3-point ELISA assays for binding, selectivity, and cross-reactivity.